Long-acting muscarinic antagonist - Mylan/Pfizer
Latest Information Update: 20 Dec 2013
At a glance
- Originator Pfizer
- Developer Mylan
- Class Small molecules
- Mechanism of Action Muscarinic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Respiratory tract disorders
Most Recent Events
- 18 Dec 2013 Clinical trials in Respiratory tract disorders in USA (Inhalation)